thiotepa has been researched along with Granulocytic Leukemia, Chronic in 6 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors studied the effects of thiotepa in eight patients with CML with persistent thrombocythemia." | 7.69 | Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. ( Cortes, JE; Kantarjian, HM; O'Brien, S; Rodriguez-Monge, EJ; Talpaz, M, 1997) |
| "Thirty-six adults with chronic myelogenous leukemia (CML) in second or greater chronic phase, accelerated phase, or blast crisis underwent marrow or blood stem cell transplantation from an HLA-matched sibling using high-dose thiotepa, busulfan and cyclophosphamide (TBC) as the preparative regimen." | 5.09 | Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. ( Andersson, B; Champlin, R; Deisseroth, AB; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, I; Körbling, M; Lee, MS; Mehra, R; Przepiorka, D; Thall, P; van Besien, K, 1999) |
| "The authors studied the effects of thiotepa in eight patients with CML with persistent thrombocythemia." | 3.69 | Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. ( Cortes, JE; Kantarjian, HM; O'Brien, S; Rodriguez-Monge, EJ; Talpaz, M, 1997) |
| "Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms." | 2.71 | Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. ( Beall, CL; Bunner, P; Devetten, MP; Ericson, SG; Lynch, JP; Qazilbash, MH; Weisenborn, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devetten, MP | 1 |
| Qazilbash, MH | 1 |
| Beall, CL | 1 |
| Bunner, P | 1 |
| Weisenborn, R | 1 |
| Lynch, JP | 1 |
| Ericson, SG | 1 |
| Martelli, MF | 2 |
| Aversa, F | 2 |
| Rodriguez-Monge, EJ | 1 |
| Cortes, JE | 1 |
| O'Brien, S | 1 |
| Talpaz, M | 1 |
| Kantarjian, HM | 1 |
| Przepiorka, D | 1 |
| Khouri, I | 1 |
| Thall, P | 1 |
| Mehra, R | 1 |
| Lee, MS | 1 |
| Ippoliti, C | 1 |
| Giralt, S | 1 |
| Gajewski, J | 1 |
| van Besien, K | 1 |
| Andersson, B | 1 |
| Körbling, M | 1 |
| Deisseroth, AB | 1 |
| Champlin, R | 1 |
| Raiola, AM | 1 |
| Van Lint, MT | 1 |
| Lamparelli, T | 1 |
| Gualandi, F | 1 |
| Mordini, N | 1 |
| Berisso, G | 1 |
| Bregante, S | 1 |
| Frassoni, F | 1 |
| Sessarego, M | 1 |
| Fugazza, G | 1 |
| Di Stefano, F | 1 |
| Pitto, A | 1 |
| Bacigalupo, A | 1 |
| Pelicci, PG | 1 |
| Terenzi, A | 1 |
| Carotti, A | 1 |
| Felicini, R | 1 |
| Mencarelli, A | 1 |
| Donti, E | 1 |
| Latini, P | 1 |
| Aristei, C | 1 |
2 trials available for thiotepa and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Graft vs | 2004 |
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Blast Crisis; Bone Marrow Transplantation; Busulfan; Cyclo | 1999 |
4 other studies available for thiotepa and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Is there any future for T-cell depleted bone marrow transplantation in chronic myeloid leukaemia?
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Female; G | 1993 |
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Humans; Leukemia, Myel | 1997 |
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Topics: Adult; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Administration Schedule; Female; Fo | 2000 |
Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, | 1991 |